<DOC>
	<DOCNO>NCT02374489</DOCNO>
	<brief_summary>Primary objective : To investigate objective response rate patient ROS1 ALK over-expressed locally advanced , metastatic intrahepatic hilar cholangiocarcinoma receive LDK378 Secondary objective : The progression-free survival , The disease control rate , The overall survival , The toxicity profile , The correlation clinical outcome potential predictive biomarker tumor response</brief_summary>
	<brief_title>A Phase II Trial LDK378 ROS1 /or ALK Over-expressed Advanced Intrahepatic Hilar Cholangiocarcinoma</brief_title>
	<detailed_description>Sample size : LDK378 consider active agent deserve development . Considering 10 % dropout rate , total 34 patient include . Step 1 : LDK378 suitable patient : Collect tumor tissue immunohistochemistry stain confirm status ROS1 ALK expression . If patient fit criterion , LDK378 750 mg ( p.o . ) daily , 3 week treatment cycle . Step 2 : Evaluation tumor response accord RECIST 1.1 version 1 . Evaluation do baseline every 6 week 2 . Evaluation perform CT MRI response define follow : - Complete response - disappearance target lesion . - Partial response - least 30 % decrease sum long diameter target lesion compare baseline sum long diameter . - Progressive disease - least 20 % increase sum long diameter target lesion compare small sum long diameter record since treatment start appearance one , new lesion , reappearance lesion disappear , clear worsen assessable disease , appearance new lesion site . - Stable disease - neither sufficient shrinkage qualify partial response sufficient increase qualify progressive disease , compare small sum long diameter since treatment start</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Klatskin Tumor</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>1.Histological cytologically confirm diagnosis intrahepatic hilar cholangiocarcinoma demonstrate ALK and/or ROS1 overexpression IHC ( 3+ ) . 2.Locally advance inoperable metastatic disease status 3.ECOG performance status 02 . 4.Aged less 20 year 75 year , time acquisition inform consent 5.Patients must recover toxicity relate prior anticancer therapy ≤ grade 2 ( CTCAE v 4.03 ) , provide concomitant medication give prior initiation treatment LDK378 . Exception criterion : patient grade alopecia allow enter treatment . 6.The follow laboratory criterion meet : •Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Hemoglobin ( Hgb ) ≥ 9 g/dL Platelets ≥ 75 x 109/L Serum total bilirubin ≤1.5 x upper limit normal ( ULN ) , except patient biliary tract obstruction statis post drainage stent may include total bilirubin ≤3.0 x ULN direct bilirubin≤ 1.5 x ULN Aspartate transaminase ( AST ) &lt; 3.0 x ULN , except patient liver metastasis , include AST &lt; 5 x ULN ; alanine transaminase ( ALT ) &lt; 3.0 x ULN , except patient liver metastasis , include ALT &lt; 5 x ULN Calculated measure creatinine clearance ( CrCL ) ≥ 30 mL/min 7.Patient must follow laboratory value follow laboratory value correct supplement within normal limit screen : Potassium ≥ 1.0 x low limit normal ( LLN ) Magnesium ≥ 1.0 x LLN Phosphorus ≥ 1.0 x LLN Total calcium ( correct serum albumin ) ≥ 1.0 x LLN 8.At least one , previously irradiate , measurable lesion accord RECIST ( version 1.1 ) 9.Willingness ability comply schedule visit , treatment plan , laboratory test procedure . 1.Patients known hypersensitivity excipients LDK378 ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) . 2.Patients symptomatic CNS metastasis neurologically unstable require increase dos steroid within 1 week prior study entry manage CNS symptom . 3.Prior therapy LDK378 . 4.Other antitumor agent systemic chemotherapy , immunotherapy target therapy within 2 week commencement study treatment . 5.Presence history malignant disease cholangiocarcinoma diagnose and/or require therapy within past year undergo active anticancer treatment . Exceptions exclusion include follow : completely resect basal cell squamous cell skin cancer , completely resect carcinoma situ type . 6.Patients known history extensive disseminate bilateral interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , obliterative bronchiolitis , clinically significant radiation pneumonitis ( i.e . affect activity daily live require therapeutic intervention ) . 7.Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) , : unstable angina within 6 month prior screen ; myocardial infarction within 6 month prior screen ; history document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 160 mm Hg and/or Diastolic Blood Pressure ( DBP ) ≥ 100 mm Hg , without antihypertensive medication ; initiation adjustment antihypertensive medication ( ) allow prior screening ; ventricular arrhythmia ; supraventricular nodal arrhythmia control medication ; cardiac arrhythmia control medication ; correct QTc ( male : QTc &gt; 450 msec ; female : QTc &gt; 470 msec ) use Bazett correction screen ECG . 8.Impaired GI function GI disease may alter absorption LDK378 inability swallow five LDK378 capsule daily . 9.Ongoing GI adverse event &gt; grade 2 ( e.g . nausea , vomit , diarrhea ) start study . 10.Receiving medication meet one follow criterion discontinue least 1 week prior start treatment LDK378 duration participation : Medication know risk prolong QT interval induce Torsades de Pointes .Strong inhibitor strong inducer CYP3A4/5 ; Medications low therapeutic index primarily metabolize CYP3A4/5 , CYP2C8 and/or CYP2C9 ; Therapeutic dose warfarin sodium ( Coumadin ) coumadinderived anticoagulant . Anticoagulants derive warfarin allow ( eg , dabigatran , rivaroxaban , apixaban ) . ; increase dos corticosteroid ; enzymeinducing anticonvulsive agent ; herbal supplement 11.Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 12.Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month last dose study treatment . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male sterilization ( least 6 month prior screen ) appropriate postvasectomy documentation absence sperm ejaculate . For female subject study vasectomized male partner sole partner subject . Combination two follow ( a+b a+c b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . In case use oral contraception , woman stable pill minimum 3 month take study treatment . 13.Sexually active male unless use condom intercourse take drug 3 month last dose study treatment . Male patient 3 month father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>